News & Announcements
-
Second FDA Rare Pediatric Disease Designation
/**/ RNS Number : 0655P IQ-AI Limited 20 May 2024 May 20, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Second U.S. FDA Rare Pediatric Disease Designation Granted to GaM For the Treatment of Pediatric-Type Diffuse High Grade Glioma (“HGG”) Further to the announcements made on 8 November 2023 and
-
IB Software Enhances Clinical Decision-Making
/**/ RNS Number : 8182O IQ-AI Limited 17 May 2024 May 17, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe AG Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces the successful deployment of its state-of-the-art software
-
Rare Pediatric Disease Designation Granted to GaM
/**/ RNS Number : 9596N IQ-AI Limited 10 May 2024 May 10, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces U.S. FDA Rare Pediatric Disease Designation Granted to GaM For the Treatment of atypical teratoid rhabdoid tumor (“ATRT”) Further to the announcement made on 8 November 2023, Imaging Biometrics (“IB”),
-
IB Announces Expanded Access Program for GaM
/**/ RNS Number : 0442N IQ-AI Limited 02 May 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Expanded Access Program for Oral Gallium Maltolate Company initiating program based on phase 1 tolerability and safety results Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has received
-
Publication of Annual Report
/**/ RNS Number : 4602M IQ-AI Limited 29 April 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Publication of Annual Report The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2023. The Annual Report will be available on the Company’s corporate website